GammaTile
Source, Brachytherapy, Radionuclide. 510(k) K221539, from Gt Medical Technologies (Tempe, AZ). Product code KXK, class 2.
As of Nov 18, 2026, K221539 is an FDA 510(k) held by Gt Medical Technologies, substantially equivalent on Nov 9, 2022 after 166 days, with no recalls tied to it in FDA's recall database.
- Review time: 166 days
- Recalls: 0
Indications for use
As the 510(k) summary states them, read from FDA's summary PDFGammaTile is indicated as a treatment for patients with newly diagnosed malignant intracranial neoplasms and patients with recurrent intracranial neoplasms.
Predicate devices
The legally marketed devices this 510(k) summary says it is substantially equivalent to, read from FDA's summary PDF- GammaTileK190839 · Gt Medical Technologies · Jan 23, 2020
Other KXK clearances
The newest 510(k)s for the same product code; their median review was 135 days; see every KXK device- OncoPatchK252296 · Oncopatch, Inc. · Dec 5, 2025
- IsoSphereK242818 · Isoaid, LLC · Jul 15, 2025
- RadianceTx Radionuclide Brachytherapy SourceK223465 · Radiance Therapeutics, Inc. · Jan 11, 2023
Record
- Document
- 510(k) summary (PDF) ↗
- Type
- Traditional
- Received
- May 27, 2022
- Review panel
- Radiology
- Regulation
- 21 CFR 892.5730
One page per 510(k), De Novo and original PMA. Recalls are those FDA's recall database ties to this number; recalls of related devices that cite another number are not shown. Refreshed weekly. Predicates are read by Arca from the text of FDA's 510(k) summary PDFs, most of them scans: a device number counts when the summary names it as a predicate or as the device it is substantially equivalent to. About 97% of those read were right on a sample we checked by hand; summaries from before 2000 often name predicates without a number, so older devices show fewer. Pivotal studies are read by a model from FDA's De Novo decision summaries and PMA SSEDs; a count or result is shown only when its numbers appear in FDA's text. openFDA device 510(k), PMA and recall files